ReviewACS chemical neuroscience2017
Classics in Chemical Neuroscience: Aripiprazole.
Review in ACS chemical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review.Current neuropharmacology · 2025Pooled it
- Efficacy and Safety of Aripiprazole in Children and Adolescents With Autism Spectrum Disorder: A Meta-Analysis.The Journal of nervous and mental diseasePooled it
- Efficacy of the Jingxin Zhidong Formula for Tic Disorders: A Randomized, Double Blind, Double Dummy, Parallel Controlled Trial.Neuropsychiatric disease and treatment · 2022Trial
- In vitro inhibition of Escherichia coli β-glucuronidase by aripiprazole.Pharmacological reports : PR · 2026Article
- The Effect of Oxcarbazepine on the Pharmacokinetics of Single-Dose Aripiprazole in a Rat Model.Medicines (Basel, Switzerland) · 2026Article
- Harnessing pyroptosis to restrain melanoma through aripiprazole.Apoptosis : an international journal on programmed cell death · 2026Article
- Dopamine DPsychological medicine · 2025Article
- Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review.Diseases (Basel, Switzerland) · 2025Review
- Bioreduction of N-(3-oxobutyl)heterocycles with flexible ring by yeast whole-cell biocatalysts.Applied microbiology and biotechnology · 2025Article
- Therapeutic Effects of Pharmacological Modulation of Serotonin Brain System in Human Patients and Animal Models of Fragile X Syndrome.International journal of molecular sciences · 2025Review
- Agar/β-Cyclodextrin Composite Cryogels for Controlled Release of Aripiprazole.Molecules (Basel, Switzerland) · 2025Article
- Aripiprazole use and lowering the risk of breast cancer in patient with schizophrenia in a national cohort study.PloS one · 2025Article
- Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.Neuropsychiatric disease and treatment · 2025Review
- The Antipsychotic Drug Aripiprazole Suppresses Colorectal Cancer by Targeting LAMP2a to Induce RNH1/miR-99a/mTOR-Mediated Autophagy and Apoptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Prenatal Immune Challenge Differentiates the Effect of Aripiprazole and Risperidone on CD200-CD200R and CX3CL1-CX3CR1 Dyads and Microglial Polarization: A Study in Organotypic Cortical Cultures.Life (Basel, Switzerland) · 2024Article
- Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole.CNS neuroscience & therapeutics · 2024Article
- Nanogels Based on N,N-Dimethylacrylamide and β-Cyclodextrin Triacrylate for Enhanced Solubility and Therapeutic Efficacy of Aripiprazole.Gels (Basel, Switzerland) · 2024Article
- Altered brain serotonin 5-HTNeuropharmacology · 2024Article
- Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.Frontiers in pharmacology · 2024Article
- What Long COVID investigators can learn from four decades of ME/CFS research.Brain behavior and immunity integrative · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Aripiprazole was the first antipsychotic developed to possess agonist properties at dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.